The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10623 malaria professionals are enjoying the free benefits of MalariaWorld today

antimalarial drugs

Not Open Access | Teratogen update: Malaria in pregnancy and the use of antimalarial drugs in the first trimester

October 21, 2020 - 09:39 -- NOT Open Access
Author(s): 
Clark RL
Reference: 
Birth Defects Res. 2020 Oct 20

Malaria is a particular problem in pregnancy because of enhanced sensitivity, the possibility of placental malaria, and adverse effects on pregnancy outcome. Artemisinin-containing combination therapies (ACTs) are the most effective antimalarials known. WHO recommends 7-day quinine therapy for uncomplicated Plasmodium falciparum malaria in the first trimester despite the superior tolerability and efficacy of 3-day ACT regimens because artemisinins caused embryolethality and/or cardiovascular malformations at relatively low doses in rats, rabbits, and monkeys.

Not Open Access | Plasmodium falciparum Replication factor C subunit 1 is involved in genotoxic stress response

October 13, 2020 - 12:53 -- NOT Open Access
Author(s): 
Sheriff O, Aniweh Y, Lai SK, Loo HL, Sze SK, Preiser PR
Reference: 
Cell Microbiol. 2020 Oct 11:e13277

About half the world's population is at risk of malaria, with Plasmodium falciparum malaria being responsible for the most malaria related deaths globally. Antimalarial drugs such as chloroquine and artemisinin are directed towards the proliferating intra-erythrocytic stages of the parasite, which is responsible for all the clinical symptoms of the disease.

NOT Open Access | Structural Basis for Blocking Sugar Uptake into the Malaria Parasite Plasmodium falciparum

October 7, 2020 - 14:42 -- NOT Open Access
Author(s): 
Jiang X, Yuan Y, Yan N, et al.
Reference: 
Cell. 2020 Oct 1;183(1):258-268.e12

Plasmodium species, the causative agent of malaria, rely on glucose for energy supply during blood stage. Inhibition of glucose uptake thus represents a potential strategy for the development of antimalarial drugs. Here, we present the crystal structures of PfHT1, the sole hexose transporter in the genome of Plasmodium species, at resolutions of 2.6 Å in complex with D-glucose and 3.7 Å with a moderately selective inhibitor, C3361.

Establishing a National Molecular Surveillance Program for the Detection of Plasmodium falciparum Markers of Resistance to Antimalarial Drugs in Haiti

October 1, 2020 - 15:38 -- Open Access
Author(s): 
Hamre KES, Pierre B, Namuyinga R, Mace K, Rogier EW, Udhayakumar V, Boncy J, Lemoine JF, Chang MA
Reference: 
Am J Trop Med Hyg. 2020 Sep 28

Chloroquine remains the first-line treatment for uncomplicated malaria in Haiti, and until recently, sulfadoxine-pyrimethamine was the second-line treatment. A few studies have reported the presence of molecular markers for resistance in Plasmodium falciparum parasites, and in vivo therapeutic efficacy studies (TESs) have been limited. Recognizing the history of antimalarial resistance around the globe and the challenges of implementing TESs in low-endemic areas, the Ministry of Health established a surveillance program to detect molecular markers of antimalarial resistance in Haiti.

Deleterious effects of malaria in pregnancy on the developing fetus: a review on prevention and treatment with antimalarial drugs

October 1, 2020 - 07:45 -- Open Access
Author(s): 
Saito M, Briand V, Min AM, McGready R
Reference: 
Lancet Child Adolesc Health. 2020 Oct;4(10):761-774

All malaria infections are harmful to both the pregnant mother and the developing fetus. One in ten maternal deaths in malaria endemic countries are estimated to result from Plasmodium falciparum infection. Malaria is associated with a 3-4 times increased risk of miscarriage and a substantially increased risk of stillbirth. Current treatment and prevention strategies reduce, but do not eliminate, malaria's damaging effects on pregnancy outcomes.

Purification and initial characterization of Plasmodium falciparum K(+) channels, PfKch1 and PfKch2 produced in Saccharomyces cerevisiae

September 23, 2020 - 09:02 -- Open Access
Author(s): 
Molbaek K, Tejada M, Ricke CH, Scharff-Poulsen P, Ellekvist P, Helix-Nielsen C, Kumar N, Klaerke DA, Pedersen PA
Reference: 
Microb Cell Fact. 2020 Sep 21;19(1):183

Resistance towards known antimalarial drugs poses a significant problem, urging for novel drugs that target vital proteins in the malaria parasite Plasmodium falciparum. However, recombinant production of malaria proteins is notoriously difficult. To address this, we have investigated two putative K+ channels, PfKch1 and PfKch2, identified in the P. falciparum genome.

NOT Open Access | Exploration of Anti-plasmodial Activity of Prunus cerasoides Buch.-Ham. ex D. Don (family: Rosaceae) and Its Wood Chromatographic Fractions

September 22, 2020 - 10:14 -- NOT Open Access
Author(s): 
Sachdeva C, Kumar S, Kaushik NK
Reference: 
Acta Parasitol. 2020 Sep 17

Increasing resistance to the currently available antimalarial drugs is a leading cause of failure to control malaria. Plant-based medicines are commonly used to manage numerous infections, making medicinal plants the best possible source of alternative antimalarial drugs. The objective of this study is therefore to identify antimalarial potential of Prunus cerasoides.

Antimalarial drugs inhibit the replication of SARS-CoV-2: an in vitro evaluation

September 15, 2020 - 14:26 -- Open Access
Author(s): 
Gendrot M, Andreani J, Pradines B, et al.
Reference: 
Travel Med Infect Dis. 2020 Sep 8:101873

In December 2019, a new severe acute respiratory syndrome coronavirus (SARS-CoV-2) causing coronavirus diseases 2019 (COVID-19) emerged in Wuhan, China. African countries see slower dynamic of COVID-19 cases and deaths. One of the assumptions that may explain this later emergence in Africa, and more particularly in malaria endemic areas, would be the use of antimalarial drugs.

Artemisinin Derivatives Stimulate DR5-Specific TRAIL-Induced Apoptosis by Regulating Wildtype P53

September 12, 2020 - 14:54 -- Open Access
Author(s): 
Zhou X, Zijlstra SN, Soto-Gamez A, Setroikromo R, Quax WJ
Reference: 
Cancers (Basel). 2020 Sep 4;12(9):E2514

Artemisinin derivatives, widely known as commercial anti-malaria drugs, may also have huge potential in treating cancer cells. It has been reported that artemisinin derivatives can overcome resistance to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in liver and cervical cancer cells. In our study, we demonstrated that artesunate (ATS) and dihydroartemisinin (DHA) are more efficient in killing colon cancer cells compared to artemisinin (ART).

Pages

Subscribe to RSS - antimalarial drugs